

2020 PNS Virtual Event

27 JUNE - 30 JUNE, 2020



Program Sunday 28 June 2020

7.00 PDT | 8.00 MDT | 9.00 CDT | 10.00 EDT | 15.00 BST | 16.00 CEST | 23.00 JST | 24.00 AEST

10.00-10.10 EDT

Presidential Welcome, Announcement of Alan J Gebhart Prize, Recognition of new Fellows of the Academy of Medical Sciences (UK), Prof. James Lupski, Estelle Benson, Dr. Chris Gibbons, & Introduction of Keynote



Pieter van Doorn, MD, PhD, President, *Erasmus MC University Medical Center, Rotterdam, The Netherlands*

10.10-10.40 EDT

COVID-19 And the Nervous System: What we Know (and Don't Know)

James Sejvar, MD, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA



Chair: Pieter van Doorn, MD, PhD, *Erasmus MC University Medical Center, Rotterdam, The Netherlands*

10.40-12.10 EDT

Clinical Trials Presentations

Chairs: Mary Reilly, MD, FRCP, FRCPI, *Institute of Neurology, London, UK;*
David Cornblath, MD, *The Johns Hopkins University, Baltimore, MD, USA*



10.40 EDT

Correlation Between Neurofilament Light Chain and Patient Outcome in Guillain-Barré Syndrome: ANX005 Phase 1b Results

Sanjay Keswani, MBBS, FRCP, *Annexon Biosciences, San Francisco, CA, USA*

10.55 EDT

Preceding Infections in Guillain-Barré Syndrome: Results from the IGOS-1000 Cohort

Sonja Leonhard, MD, *Erasmus University Medical Center, Rotterdam, The Netherlands*

Program

Sunday 28 June 2020

- 11.10 EDT **Pharmacokinetics of IVIg and Outcome in the Second IVIg Dose in Guillain-Barré Syndrome (SID-GBS) Trial Data: A Validation Study**
Christa Walgaard, MD, *Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands*
- 11.25 EDT **Effects of Progressive Resistance Training in Patients with Type 2 Diabetic Polyneuropathy: A Randomized Single-blinded Controlled Trial**
Karolina Khan, MD, PhD, *Aarhus University, Aarhus, Denmark*
- 11.40 EDT **Efficacy and Safety of 3 Different Dosages of IVIG (NewGam) in Patients with CIDP (ProCID Study)**
David Cornblath, MD, *The Johns Hopkins University, Baltimore, MD, USA*
- 11.55 EDT **Escalation Treatment with Cyclophosphamide, Rituximab and Bortezomib in CIDP: Real-life Retrospective Analysis in 201 Patients**
Jeremias Motte, MD, *Ruhr-University Bochum, Bochum, Germany*

12.10-12.30 EDT Break

12.30-14.00 EDT Platform Presentations



Chairs: **Charlotte Sumner, MD**, *Johns Hopkins Medicine, Baltimore, MD, USA*; **Luis Querol, MD, PhD**, *Hospital de Sant Pau, Barcelona, Spain*

- 12.30 EDT **MTORC1 and 2 Signaling: Double the Trouble in Diabetic Neuropathy**
Stephanie Eid, PhD, *University of Michigan, Ann Arbor, MI, USA*
- 12.45 EDT **Characterization of a Late Onset CMT1B Mouse Model: The Role of P0 in Schwann Cell-Axon Relationship**
Ghjuvan Shackleford, PhD, *San Raffaele Hospital Scientific Institute, Milano, Italy*
- 13.00 EDT **Serum Neurofilament Light Chain Predicts Prognosis in Patients with Guillain-Barré Syndrome**
Lorena Martín-Aguilar, MD, *Hospital de la Santa Creu i Sant Pau, Barcelona, Spain*
- 13.15 EDT **Biallelic Mutations in Sord are a Common Cause of Potentially Treatable Genetic Neuropathy**
Andrea Cortese, MD, PhD, *UCL Institute of Neurology, London, UK*
- 13.30 EDT **New Insights into the Active Transport of Paclitaxel into the Sensory Neuron**
Ines Muke, PhD, *University Hospital Cologne, Cologne, Germany*
- 13.45 EDT **The Integrated Stress Response Contributes to Disease in tRNA Synthetase-Associated Neuropathies**
Robert Burgess, PhD, *The Jackson Laboratory, Bar Harbor, ME, USA*

14.00-14.10 EDT Thank you, Farewell

Pieter van Doorn, MD, PhD, *Erasmus MC University Medical Center, Rotterdam, The Netherlands*

2020 PNS Virtual Event

27 JUNE – 30 JUNE, 2020



INC Program Saturday 27 June 2020

6.55 PDT | 7.55 MDT | 8.55 CDT | 9.55 EDT | 14.55 BST | 15.55 CEST | 22.55 JST | 23.55 AEST

9.55 – 12.05 EDT

INFLAMMATORY NEUROPATHY CONSORTIUM (INC)

9.55-10.00 EDT

Welcome & Introduction



Peter Van den Bergh, MD, PhD, INC Chair, *University Hospitals St-Luc, Brussels, Belgium*

10.00-10.25 EDT

Novel Opportunities for Body Fluid Biomarker Development for Neurological Diseases



Charlotte Teunissen, PhD, *Neurochemistry Lab, Amsterdam University Medical Centers, Amsterdam, The Netherlands*

Chair: Robert Hadden, BM, BCh, FRCP, PhD, *King's College Hospital, London, UK*

10.25-11.15 EDT

Oral Poster Presenters

Chair: Ruth Huizinga, PhD, *Erasmus MC, Rotterdam, The Netherlands*

10.25 EDT

Development of an Anti-GM1 Antibody-Specific Therapy for Guillain-Barré Syndrome and Multifocal Motor Neuropathy

Butrint Aliu, MSc, *University of Basel, Basel, Switzerland*

INC Program

Saturday 27 June 2020

10.35 EDT **Association of Serum Neurofilament Light Chain Levels with Clinicopathology and NF155 Autoantibodies in Patients with CIDP**

Yuki Fukami, MD, Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan

10.45 EDT **Blockade of Colony Stimulating Factor 1 Receptor Improves Inflammatory Nerve Injury**

Tong Gao, PhD, University of Texas Health Science Center, Houston, TX, USA

10.55 EDT **Cerebrospinal Fluid Protein Level and Cell Count in Diagnosis and Prognosis of Guillain-Barré Syndrome**

Helle Al-Hakem, BSc, Aarhus University Hospital, Aarhus, Denmark

11.05 EDT **Anti-Paranodal Autoantibodies in a Large GBS and Acute-onset CIDP Cohort with IgG Subclass Switch from Acute to Chronic Stage in One Patient**

Luise Appeltshauser, MD, Department of Neurology, University Hospital of Würzburg, Würzburg, Germany

11.15-11.40 EDT **Update on the Nonsystemic Vasculitic Neuropathies**

Michael Collins, MD, Medical College of Wisconsin, Milwaukee, WI, USA

Chair: Robert Hadden, BM, BCh, FRCP, PhD, King's College Hospital, London, UK



11.40-12.00 EDT **INC Project Updates**

Chair: Jeffrey Allen, MD, University of Minnesota, Minneapolis, MN, USA

11.40 EDT **International GBS Outcome Study (IGOS)**

Bart Jacobs, MD, PhD, Erasmus MC University Medical Center, Rotterdam, The Netherlands

11.45 EDT **INCbase**

Filip Eftimov, MD, PhD, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, The Netherlands

11.50 EDT **Italian Muticenter Database on Multifocal Motor Neuropathy (IDAM)**

Eduardo Nobile-Orazio, MD, PhD, Milan University, Milan, Italy

11.55 EDT **Building a Prospective Cohort of Patients with Idiopathic or Inflammatory Sensory Neuropathy**


Jean-Christophe Antoine, MD, Chu Hopital de Bellevue, Saint-Étienne, France

12.00-12.05 EDT **Closing Remarks**

Peter Van den Bergh, MD, PhD, INC Chair, University Hospitals St-Luc, Brussels, Belgium

2020 PNS Virtual Event

27 JUNE – 30 JUNE, 2020



TNC Program Saturday 27 June 2020

11.30 PDT | 12.30 MDT | 13.30 CDT | 14.30 EDT | 19.30 BST | 20.30 CEST | 3.30 JST (28 June) | 4.30 AEST (28 June)

14.30 – 16.45 EDT

TOXIC NEUROPATHY CONSORTIUM [TNC]

14.30-14.35 EDT

Welcome & Overview of TNC Content



Guido Cavaletti, MD, TNC Chair, *University of Milano-Bicocca, Monza (I), Milan, Italy*

14.35-15.05 EDT

Toxic Neuropathies



Wolfgang Grisold, MD, PhD, FAAN, *Ludwig Boltzmann Institute for Experimental und Clinical Traumatology, Vienna, Austria*

Chair: Ellen Smith, PhD, APRN, AOCN®, FAAN, *University of Michigan School of Nursing, Ann Arbor, MI, USA*

TNC Program

Saturday 27 June 2020

15.05-15.35 EDT

Pathogenic Role of Tubulin Post Translational Modifications in Axon Degeneration

Francesca Bartolini, PhD, *Columbia University, New York, NY, USA*

Chair: Ahmet Hoke, MD, PhD, *Johns Hopkins University, Baltimore, MD, USA*



15.35-15.50 EDT

Toxic Neuropathy Consortium Activities Update

Andreas Argryiou, PhD, *Saint Andrew's General Hospital, Patras, Greece*

15.50-16.40 EDT

Abstract Presentations

Chairs: Sandra Rieger, PhD, *University of Miami, Coral Gables, FL, USA;*

Susanna Park, PhD, *University of Sydney, Sydney, Australia*

15.50 EDT

Molsidomine Provides Neuroprotection Against Vincristine-induced Peripheral Neuropathy Through Soluble Guanylyl Cyclase Activation

Francesco Lotti, PhD, *Columbia University Medical Center, New York, NY, USA*

16.00 EDT

Usefulness of the Nerve Conduction Studies for Grading the Severity of Chemotherapy-Induced Peripheral Neurotoxicity

Roser Velasco, PhD, MD, *University Hospital of Bellvitge, Barcelona, Spain*

16.10 EDT

Chemotherapy-induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-term Quality of Life

Eva Battaglini, PhD, *University of New South Wales, Sydney, Australia*

16.20 EDT

Responsiveness and Minimal Clinical Important Difference (MCID) of the Total Neuropathy Score Clinical and Nurse Versions in CIPN

Paola Alberti, MD, PhD, *University of Milano-Bicocca, Monza, Italy*

16.30 EDT

Fibrates, Peroxisome Proliferator-activated Receptor – Agonists, for the Treatment of Paclitaxel-Induced Peripheral Neuropathy

Martial Caillaud, PhD, *Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA*

16.40-16.45 EDT

Thank you, Farewell

Guido Cavaletti, MD, TNC Chair, *University of Milano-Bicocca, Monza (I), Milan, Italy*

2020 PNS Virtual Event

27 JUNE – 30 JUNE, 2020



CMTR Program Monday 29 June 2020

7.00 PDT | 8.00 MDT | 9.00 CDT | 10.00 EDT | 15.00 BST | 16.00 CEST | 23.00 JST | 24.00 AEST

10.00 – 12.10 EDT

CHARCOT-MARIE-TOOTH & RELATED NEUROPATHIES CONSORTIUM [CMTR]

10.00-10.05 EDT

Welcome, Overview of CMTR, James Lupski CMTR Lifetime Achievement Award



Michael Shy, MD, CMTR Chair, *University of Iowa, Carver College of Medicine, Iowa City, IA, USA*

10.05-10.35 EDT

Research and Clinical Exome Sequencing (cES) in the Study of Neurodevelopmental and Neurodegenerative Disease



James R Lupski, MD, PhD, DSc (hon), *Baylor College of Medicine, Houston, TX, USA*
Chairs: **Michael Shy, MD**, *University of Iowa, Carver College of Medicine, Iowa City, IA, USA*; **Stephan Zuchner, MD, PhD**, *University of Miami Miller School of Medicine, Miami, FL, USA*

CMTR Program

Monday 29 June 2020

10.35-11.05 EDT



Exploration of Giant Axonal Neuropathy Unveils Common Pathological Mechanisms amongst CMT Diseases: The Obvious and the Unexpected

Pascale Bomont, PhD, INM-INSERM, University of Montpellier, Montpellier, France
Chairs: Vincent Timmerman, MSc, PhD, University of Antwerp, Antwerp, Belgium;
Steven S. Scherer, MD, PhD, The University of Pennsylvania, Philadelphia, PA, USA

11.05-11.35 EDT



FAP-What's New?

Merrill Benson, MD, Indiana University, Indianapolis, IN, USA
Chairs: Mary Reilly, MD, UCL Institute of Neurology, London, UK;
Michael Polydefkis, MD, MHS, Johns Hopkins Medicine, Baltimore, MD, USA

11.35-12.05 EDT



Mitofusins in Axonal Degeneration and Neuroprotection

Robert Baloh, MD, PhD, Cedars-Sinai Medical Center, Los Angeles, CA, USA
Chairs: Robert Burgess, PhD, The Jackson Laboratory, Bar Harbor, ME, USA;
John Svaren, PhD, University of Wisconsin, Madison, WI, USA

12.05-12.10 EDT

Thank you, Farewell

Michael Shy, MD, CMTR Chair, University of Iowa, Carver College of Medicine, Iowa City, IA, USA

2020 PNS Virtual Event

27 JUNE – 30 JUNE, 2020



IDNC Program Tuesday 30 June 2020

7.00 PDT | 8.00 MDT | 9.00 CDT | 10.00 EDT | 15.00 BST | 16.00 CEST | 23.00 JST | 24.00 AEST

10.00 – 12.10 EDT

INTERNATIONAL DIABETES NEUROPATHY CONSORTIUM (IDNC)

10.00-10.05 EDT

Welcome & Introduction



Christopher Gibbons, MD, IDNC Chair, *Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA*

10.05-12.05 EDT

IDNC Platform Presentations

Chairs: **James Russell, MD, PhD**, Professor of Neurology, University of Maryland, MD, USA; **Vera Fridman, MD**, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

10.05 EDT

Increased Peptidergic Fiber Density and Macrophage Infiltration in The Skin in Painful Diabetic Polyneuropathy

Pall Karlsson, PhD, Danish Pain Research Center, Aarhus University, Aarhus, Denmark

10.20 EDT

Neuronal LXR Regulates Neuregulin 1 Expression and Sciatic Nerve-Associated Cell Signaling in Western Diet-fed Rodents

Chaitanya Gavini, PhD, Loyola University Chicago, Maywood, IL, USA

IDNC Program

Tuesday 30 June 2020

- 10.35 EDT **Functional Characterization of Human Variants in the Pro-Degenerative Gene SARM1 and their Implication in Peripheral Neuropathies**
Mirlinda Ademi, MD, *University of Cambridge, Cambridge, United Kingdom*
- 10.50 EDT **Protective Role of Schwann Cell p75NTR against Small Fiber Degeneration in Diabetic Neuropathy**
Nádia Pereira Gonçalves, DVM, PhD, *Department of Biomedicine, Aarhus University, Aarhus, Denmark*
- 11.05 EDT **Fecal Transplantation Improves Peripheral Pain in Western Diet Murine Model**
Raiza Bonomo, MS, *Loyola University Chicago, Maywood, IL, USA*
- 11.20 EDT **Cardiovascular Health Score and Chronic Axonal Polyneuropathy: A Population-based Cohort Study**
Noor Taams, MD, *Erasmus Medical Center, Rotterdam, The Netherlands*
- 11.35 EDT **Microphysiological Modeling of Spinal Cord Synaptic Transmission Through 3-Dimensional Culture of Embryonic Rodent and Human-Derived Neural Tissue**
Kevin Pollard, PhD, *Tulane University, New Orleans, LA, USA*
- 11.50 EDT **Novel Plasma Metabolomic Signatures Associated with Diabetic Neuropathy in a Cohort with Screen-Tested Type 2 Diabetes: ADDITION-Denmark**
Amy Rumora, PhD, *University of Michigan, Ann Arbor, MI, USA*

12.05-12.10 EDT

Closing Remarks

James Russell, MD, PhD, *Professor of Neurology, University of Maryland, MD, USA*

